LumiThera announced CE Mark approval for the LT-300 Light Delivery System for the treatment of dry age-related macular degeneration (AMD).
LumiThera is a commercial stage medical device company focused on developing noninvasive photobiomodulation (PBM) therapies for ocular disorders and disease.
“The CE mark allows LumiThera to begin commercialization throughout the 28 EU member states and coincides with the initiation of the LIGHTSITE II clinical study in select European sites in the upcoming months,” Clark Tedford, PhD, LumiThera President and CEO, said in a company news release. “We are excited to be able to offer a safe and effective early stage clinical intervention for patients with dry AMD.”
“It is very exciting to see the development of PBM treatment for dry AMD patients,” Samuel Markowitz, MD, Department of Ophthalmology and Vision Sciences, University of Toronto, said in the news release. “These patients have limited options and losing their central vision is horribly debilitating to their quality of life. The previous LIGHTSITE I Clinical Studies demonstrated that PBM therapy was most beneficial in early stage dry AMD patients. It was also determined that retreatments at scheduled intervals will be needed to maintain clinical benefits.”
“PBM may change the way we think about treating dry AMD,” says Dr. Robert Devenyi, Ophthalmologist-in-Chief and Director of Retinal Services, UHN, University of Toronto. “Until now we just waited and watched the patients lose vision with limited therapeutic options. Now we may have a treatment that can target improvement in visual outcomes and reduce a key component of the pathology. The next step is to confirm the early results in the multi-center LIGHTSITE II trial and work with ophthalmology medical community in establishing best treatment practices.”